pipeline: clean 3 stale queue duplicates
Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>
This commit is contained in:
Teleo Agents
parent
7f1e39a31c
commit
1a3ee7e245
3 changed files with 0 additions and 263 deletions
|
|
@ -1,78 +0,0 @@
|
||||||
---
|
|
||||||
type: source
|
|
||||||
title: "Equity in Digital Health: Access and Utilization of Remote Patient Monitoring, Medical Apps, and Wearables in Underserved Communities"
|
|
||||||
author: "Omolola Adepoju, Patrick Dang, Holly Nguyen, Jennifer Mertz"
|
|
||||||
url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11450565/
|
|
||||||
date: 2024-09-01
|
|
||||||
domain: health
|
|
||||||
secondary_domains: []
|
|
||||||
format: article
|
|
||||||
status: processed
|
|
||||||
priority: high
|
|
||||||
tags: [digital-health, equity, remote-patient-monitoring, wearables, health-disparities, digital-divide, hypertension]
|
|
||||||
processed_by: vida
|
|
||||||
processed_date: 2026-03-31
|
|
||||||
claims_extracted: ["generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md"]
|
|
||||||
enrichments_applied: ["only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md", "the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access.md"]
|
|
||||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
|
||||||
---
|
|
||||||
|
|
||||||
## Content
|
|
||||||
|
|
||||||
Published 2024 in a peer-reviewed journal (Adepoju et al., PMC11450565).
|
|
||||||
|
|
||||||
**Study focus:** Assess access to and utilization of remote patient monitoring (RPM), medical apps, and wearables in racially diverse, lower-income populations.
|
|
||||||
|
|
||||||
**Key findings — the equity tension:**
|
|
||||||
|
|
||||||
1. **Despite high smart device ownership** in the populations studied, utilization of digital health tools remained lower than in higher-income populations. High device ownership does not translate to health-improving app usage.
|
|
||||||
|
|
||||||
2. **Medical app usage disparities by income:** Usage was significantly lower among individuals with:
|
|
||||||
- Income levels below $35,000
|
|
||||||
- Education below a bachelor's degree
|
|
||||||
- Males
|
|
||||||
|
|
||||||
3. **Barriers to RPM equity:**
|
|
||||||
- Cost of technology (devices, data plans)
|
|
||||||
- Poor internet connectivity
|
|
||||||
- Poor health literacy
|
|
||||||
- Transportation barriers (ironic — RPM is supposed to remove this barrier, but onboarding requires it)
|
|
||||||
|
|
||||||
4. **Policy infrastructure attempted:** Affordability Connectivity Program (ACP) sought to provide low-income households with discounted broadband and devices — but ACP was discontinued in June 2024 (federal budget failure).
|
|
||||||
|
|
||||||
5. **Core finding: Digital health tends to benefit more affluent and privileged groups more than those less privileged** — even when technology access is nominally equal, health literacy and navigation barriers concentrate benefits upward.
|
|
||||||
|
|
||||||
**Contrast with JAMA Network Open meta-analysis (2024):** That meta-analysis showed tailored digital health works for disparity populations; this study explains WHY generic deployment fails — the design matters as much as the technology.
|
|
||||||
|
|
||||||
## Agent Notes
|
|
||||||
|
|
||||||
**Why this matters:** This is the critical counterweight to the JAMA meta-analysis. The two sources together create a precise claim: digital health can close hypertension disparities IF specifically designed for disparity populations, but generic deployment reproduces and potentially widens existing disparities. The "if tailored" qualifier is not a minor caveat — it requires intentional design, reimbursement alignment, and literacy/navigation support that commercial digital health products do not currently provide at scale.
|
|
||||||
|
|
||||||
**What surprised me:** The discontinuation of the Affordability Connectivity Program in June 2024 removed the primary federal infrastructure for digital health equity. At the exact moment digital health is being positioned as the solution to the hypertension failure, the connectivity subsidy that made it accessible to low-income households was terminated.
|
|
||||||
|
|
||||||
**What I expected but didn't find:** Data on whether RPM programs that are specifically deployed in safety-net health systems (FQHCs, VA) show the equity premium that the JAMA meta-analysis's "tailored" interventions do. The FQHC/VA population would be the best test of real-world equity-achieving RPM.
|
|
||||||
|
|
||||||
**KB connections:**
|
|
||||||
- `only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control...` — digital health is a proposed solution; this source shows it requires intentional design
|
|
||||||
- `the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served` — same structural pattern in mental health and digital health generally
|
|
||||||
- `medical care explains only 10-20 percent of health outcomes...` — if digital health primarily reaches advantaged populations, it reinforces the SDOH advantage of those populations without reaching the 80-90% SDOH-burdened majority
|
|
||||||
|
|
||||||
**Extraction hints:**
|
|
||||||
- New claim: "Generic digital health deployment reproduces existing disparities by disproportionately benefiting higher-income, higher-education users despite nominal technology access equity, because health literacy and navigation barriers concentrate digital health benefits upward"
|
|
||||||
- Pair with JAMA meta-analysis to create a scoped divergence: "tailored digital health works for disparities" vs. "generic deployment widens disparities"
|
|
||||||
|
|
||||||
**Context:** ACP termination (June 2024) removed the federal connectivity subsidy that was the main infrastructure mitigation. The TEMPO pilot (Dec 2025) includes a "rural adjustment" for CMS ACCESS participants but does not address urban food desert populations or the literacy/navigation barriers documented here.
|
|
||||||
|
|
||||||
## Curator Notes
|
|
||||||
|
|
||||||
PRIMARY CONNECTION: `only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md`
|
|
||||||
|
|
||||||
WHY ARCHIVED: Creates a necessary tension with the JAMA meta-analysis — these two sources together define exactly what "digital health can and can't do" for hypertension equity. The extractor should treat them as a pair.
|
|
||||||
|
|
||||||
EXTRACTION HINT: Extract the claim that generic vs. tailored is the key variable. Flag for potential divergence file with the JAMA meta-analysis source. The real claim is "digital health's equity value is design-dependent, not technology-dependent."
|
|
||||||
|
|
||||||
|
|
||||||
## Key Facts
|
|
||||||
- The Affordability Connectivity Program (ACP) was discontinued in June 2024, removing federal subsidies for low-income household broadband and devices
|
|
||||||
- Medical app usage was significantly lower among individuals with income below $35,000, education below bachelor's degree, and males in the study population
|
|
||||||
- Barriers to RPM equity included cost of technology (devices, data plans), poor internet connectivity, poor health literacy, and transportation barriers for onboarding
|
|
||||||
|
|
@ -1,94 +0,0 @@
|
||||||
---
|
|
||||||
type: source
|
|
||||||
title: "Cardiovascular Disease Mortality Trends, 2010–2022: An Update with Final Data"
|
|
||||||
author: "American Journal of Preventive Medicine"
|
|
||||||
url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11757076/
|
|
||||||
date: 2024-09-01
|
|
||||||
domain: health
|
|
||||||
secondary_domains: []
|
|
||||||
format: article
|
|
||||||
status: enrichment
|
|
||||||
priority: high
|
|
||||||
tags: [CVD-mortality, cardiovascular, stagnation, midlife, working-age, excess-deaths, COVID, 2010-2022, AJPM]
|
|
||||||
processed_by: vida
|
|
||||||
processed_date: 2026-03-31
|
|
||||||
enrichments_applied: ["hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md"]
|
|
||||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
|
||||||
---
|
|
||||||
|
|
||||||
## Content
|
|
||||||
|
|
||||||
Published 2024 in *American Journal of Preventive Medicine* (update of the 2023 preliminary analysis with final NVSS data). PubMed ID: 39321995.
|
|
||||||
|
|
||||||
**Study design:** Analysis of National Vital Statistics System final Multiple Cause of Death files for US adults aged ≥35 years, 2010–2022. Calculated age-adjusted mortality rates (AAMR) and excess deaths 2020–2022.
|
|
||||||
|
|
||||||
**Key findings:**
|
|
||||||
|
|
||||||
**Overall trajectory:**
|
|
||||||
- CVD AAMR declined **8.9%** from 2010 to 2019 (456.6 → 413.0 per 100,000)
|
|
||||||
- Then **increased 9.3%** from 2019 to 2022 to **454.5 per 100,000**
|
|
||||||
- The 2022 AAMR approximates the **2010 rate** — the entire decade of CVD progress was erased
|
|
||||||
|
|
||||||
**Age ≥35 specific 2022 figure:**
|
|
||||||
- CVD AAMR (adults ≥35): **434.6 per 100,000 in 2022** (down from 451.8 in 2021 peak)
|
|
||||||
- The most recent year with a similarly high CVD AAMR was **2012** (434.7 per 100,000)
|
|
||||||
- So in 2022, we were at CVD mortality levels not seen since 2012 — a 10-year setback
|
|
||||||
|
|
||||||
**Midlife impact:**
|
|
||||||
- Adults aged **35–54**: Increases from 2019 to 2022 **"eliminated the reductions achieved over the preceding decade"**
|
|
||||||
- Adults aged **65–74**: Same pattern — decade of gains erased
|
|
||||||
- This is the most significant finding for the harvesting-vs-structural question: COVID harvesting would primarily affect the very old; elimination of gains in 35–54 suggests structural causes beyond harvesting
|
|
||||||
|
|
||||||
**Excess deaths:**
|
|
||||||
- **228,524 excess CVD deaths** from 2020 to 2022
|
|
||||||
- That's **9% more CVD deaths** than expected based on 2010–2019 trends
|
|
||||||
- Even if some are COVID-direct (COVID-induced MI, stroke), the working-age pattern is inconsistent with pure harvesting
|
|
||||||
|
|
||||||
**2023 data (partial, from other NCHS sources):**
|
|
||||||
- All-cause mortality AAMR decreased 6.0% from 2022 to 2023 (798.8 → 750.5 per 100,000)
|
|
||||||
- CVD in this NCHS data brief shows 2022 "still above pre-pandemic 2019 levels" for cardiometabolic component
|
|
||||||
- 2023 improvements likely reflect COVID dissipation, not CVD structural reversal
|
|
||||||
|
|
||||||
**Companion paper — AJPM 2023 (excess deaths 2010–2022 preliminary):**
|
|
||||||
- Same team, preliminary data: same 228,524 excess deaths finding, 9% excess
|
|
||||||
- 2024 update confirms with final data: the preliminary estimates were accurate
|
|
||||||
|
|
||||||
**Companion paper — PNAS 2023 "double jeopardy":**
|
|
||||||
- "US is experiencing a 'double jeopardy' driven by both mid-life and old age mortality trends, but more so by older-age mortality"
|
|
||||||
- This nuances the midlife focus: older-age is the larger driver numerically, but midlife is the more structural signal
|
|
||||||
|
|
||||||
## Agent Notes
|
|
||||||
|
|
||||||
**Why this matters:** This closes the "COVID harvesting test" thread from Sessions 14-15. The key question was: is the 2022 CVD AAMR still elevated above pre-pandemic levels, or has harvesting run its course? Answer: **2022 is at the 2012 level** — a 10-year setback. The 35–54 age group's erasure of an entire decade's gains is the most important data point for the structural interpretation. COVID harvesting affects the frail and elderly; working-age CVD increases from 2019–2022 suggest structural disease load, not just mortality timing.
|
|
||||||
|
|
||||||
**What surprised me:** The "double jeopardy" framing from PNAS — the LE stagnation is driven MORE by older-age than midlife. This complicates the narrative that midlife structural failure is the primary driver. However, the older-age component may itself be the long-term consequence of midlife structural failure in earlier cohorts (accumulated cardiometabolic damage from the 1990s-2010s reaching expression at age 65+).
|
|
||||||
|
|
||||||
**What I expected but didn't find:** Hypertension-specific sub-analysis in this paper. The AJPM paper covers CVD overall and subtypes (IHD, stroke). For hypertension-specific CVD sub-type trends, the JACC 2025 data from Session 15 remains the primary source.
|
|
||||||
|
|
||||||
**KB connections:**
|
|
||||||
- `hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment...` — this AJPM paper covers overall CVD; the hypertension doubling is the specific sub-type claim
|
|
||||||
- Sessions 10-15 accumulated: AJE Abrams stagnation, PNAS 2026 cohort mortality, CDC 2024 LE record — this AJPM paper provides the INTERMEDIATE data (2022 setback, 2023 partial recovery)
|
|
||||||
- The harvesting test is now partially resolved: midlife 35-54 gains erasure suggests structural not just harvesting
|
|
||||||
|
|
||||||
**Extraction hints:**
|
|
||||||
- New claim: "US cardiovascular disease AAMR in 2022 returned to 2012 levels, erasing a decade of progress — with adults 35–54 experiencing elimination of the preceding decade's CVD gains, consistent with structural disease load rather than COVID harvesting"
|
|
||||||
- This should be extracted as an update/amendment to the stagnation cluster, not a standalone new claim
|
|
||||||
|
|
||||||
**Context:** This is the "with final data" update — preferred over the 2023 preliminary analysis. The 2024 paper is definitive for the 2010-2022 period.
|
|
||||||
|
|
||||||
## Curator Notes
|
|
||||||
|
|
||||||
PRIMARY CONNECTION: `hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md` (and the broader CVD stagnation cluster)
|
|
||||||
|
|
||||||
WHY ARCHIVED: Closes the COVID harvesting test thread. Confirms the 2022 CVD AAMR is at 2012 levels with the 35-54 age group showing full decade erasure — key evidence for structural vs. transient interpretation of CVD stagnation.
|
|
||||||
|
|
||||||
EXTRACTION HINT: This is a data update to the stagnation cluster, not a new standalone claim. The extractor should enrich the existing stagnation claims with the midlife 35-54 "decade of gains erased" finding. The PNAS "double jeopardy" framing (older-age more numerically significant than midlife) should be noted as a scope qualifier.
|
|
||||||
|
|
||||||
|
|
||||||
## Key Facts
|
|
||||||
- CVD AAMR declined 8.9% from 2010 to 2019 (456.6 → 413.0 per 100,000)
|
|
||||||
- CVD AAMR increased 9.3% from 2019 to 2022 to 454.5 per 100,000
|
|
||||||
- 2022 CVD AAMR for adults ≥35 was 434.6 per 100,000, matching 2012 levels (434.7)
|
|
||||||
- 228,524 excess CVD deaths occurred 2020-2022, representing 9% above expected
|
|
||||||
- All-cause mortality AAMR decreased 6.0% from 2022 to 2023 (798.8 → 750.5 per 100,000)
|
|
||||||
- PNAS 2023 companion paper describes US experiencing 'double jeopardy' driven more by older-age than midlife mortality numerically
|
|
||||||
|
|
@ -1,91 +0,0 @@
|
||||||
---
|
|
||||||
type: source
|
|
||||||
title: "FDA TEMPO Pilot: Technology-Enabled Meaningful Patient Outcomes for Digital Health Devices"
|
|
||||||
author: "U.S. Food and Drug Administration"
|
|
||||||
url: https://www.fda.gov/medical-devices/digital-health-center-excellence/tempo-digital-health-devices-pilot-frequently-asked-questions
|
|
||||||
date: 2025-12-05
|
|
||||||
domain: health
|
|
||||||
secondary_domains: []
|
|
||||||
format: article
|
|
||||||
status: processed
|
|
||||||
priority: high
|
|
||||||
tags: [FDA, TEMPO, digital-health, enforcement-discretion, CMS-ACCESS, hypertension, cardio-kidney-metabolic, regulation, reimbursement]
|
|
||||||
processed_by: vida
|
|
||||||
processed_date: 2026-03-31
|
|
||||||
claims_extracted: ["tempo-pilot-creates-medicare-digital-health-pathway-while-medicaid-coverage-contracts.md"]
|
|
||||||
enrichments_applied: ["the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification.md", "CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo.md", "rpm-technology-stack-enables-facility-to-home-care-migration-through-ai-middleware-that-converts-continuous-data-into-clinical-utility.md"]
|
|
||||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
|
||||||
---
|
|
||||||
|
|
||||||
## Content
|
|
||||||
|
|
||||||
**Announcement date:** December 5, 2025 (Federal Register notice). Statements of interest opened January 2, 2026.
|
|
||||||
|
|
||||||
**What it is:** FDA's Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot — a voluntary program where FDA exercises enforcement discretion for digital health devices used within CMS's CMMI ACCESS model. This creates the first combined **FDA enforcement-discretion + CMS reimbursement** pathway for digital health devices targeting chronic conditions.
|
|
||||||
|
|
||||||
**Four CMMI ACCESS clinical use areas (TEMPO targets):**
|
|
||||||
1. **Early cardio-kidney-metabolic (early CKM):** hypertension, dyslipidemia, obesity/overweight with central adiposity marker, prediabetes
|
|
||||||
2. **CKM:** diabetes, chronic kidney disease, atherosclerotic cardiovascular disease
|
|
||||||
3. **Musculoskeletal:** chronic musculoskeletal pain
|
|
||||||
4. **Behavioral health:** depression or anxiety
|
|
||||||
|
|
||||||
**Hypertension is explicitly in scope** (early CKM category).
|
|
||||||
|
|
||||||
**Enforcement discretion mechanics:**
|
|
||||||
- Manufacturers in TEMPO may deploy software, wearables, sensor-based, or AI-enabled devices in routine care settings
|
|
||||||
- Must collect and report real-world evidence
|
|
||||||
- Work toward FDA marketing submission evidence package
|
|
||||||
- FDA does not enforce applicable regulatory requirements during pilot
|
|
||||||
|
|
||||||
**Scale:** Up to **~10 manufacturers per clinical use area** selected. This means ~10 digital health products targeting hypertension can operate under TEMPO. National scale for hypertension management is ~73 million affected adults — so TEMPO covers a research fraction, not a population solution.
|
|
||||||
|
|
||||||
**Equity dimension:** CMS ACCESS model includes a fixed adjustment for **rural patients** in qualifying tracks. No specific urban food desert or income-stratified equity measure. The ACP (Affordability Connectivity Program) subsidy for internet access was discontinued June 2024, removing the connectivity infrastructure TEMPO-eligible patients in low-income urban settings would need.
|
|
||||||
|
|
||||||
**Timeline:**
|
|
||||||
- January 2, 2026: Statements of interest open
|
|
||||||
- ~March 2, 2026: FDA sends follow-up requests to selected manufacturers
|
|
||||||
- March 2026 onward: Selected manufacturers begin deployment
|
|
||||||
|
|
||||||
**Legal/regulatory analysis sources:** Wilson Sonsini (ACCESS + TEMPO overview), Manatt (two-door entryway), ArentFox (five things to know), McDermott (race for digital health access).
|
|
||||||
|
|
||||||
**Key mechanism:** ACCESS Model CMS reimbursement + TEMPO FDA discretion = first time Medicare will pay for uncleared digital health devices in a real-world evidence collection setting. This creates a genuine market entry pathway that didn't exist before January 2026.
|
|
||||||
|
|
||||||
## Agent Notes
|
|
||||||
|
|
||||||
**Why this matters:** TEMPO is the regulatory infrastructure that could eventually enable FDA-deregulated digital health to reach Medicare patients with hypertension. The January 2026 FDA CDS guidance + TEMPO + CMS ACCESS model are three interlocking pieces of a new digital health access architecture. If this proves effective, it creates a replication template. BUT: scale is tiny (10 manufacturers, Medicare patients only, research setting) — this is a feasibility pilot, not a population-level deployment.
|
|
||||||
|
|
||||||
**What surprised me:** The explicit inclusion of hypertension in the early CKM category. The FDA is formally acknowledging that hypertension digital health needs a structured pathway — not just the general "enforcement discretion" it provided in the January 2026 CDS guidance. TEMPO is more targeted and more meaningful for the hypertension problem than the general guidance.
|
|
||||||
|
|
||||||
**What I expected but didn't find:** Any equity requirement beyond rural adjustment. The TEMPO pilot applies to CMS ACCESS model participants — these are Medicare patients (65+). The population with the worst hypertension control rates (low-income, food-insecure, working-age) is primarily in Medicaid, not Medicare. OBBBA is systematically removing Medicaid coverage for exactly this population. So TEMPO + OBBBA creates a structural divergence: FDA is creating digital health infrastructure for Medicare hypertension patients while OBBBA removes coverage for Medicaid hypertension patients.
|
|
||||||
|
|
||||||
**KB connections:**
|
|
||||||
- `the FDA now separates wellness devices from medical devices based on claims not sensor technology...` — January 2026 CDS guidance; TEMPO is the next layer of this deregulatory architecture
|
|
||||||
- `CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system...` — TEMPO formalizes a similar two-speed system at an earlier stage (pre-clearance vs. cleared)
|
|
||||||
- `rpm-technology-stack-enables-facility-to-home-care-migration...` — TEMPO enables RPM deployment at the infrastructure level
|
|
||||||
- `only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control...` — TEMPO is the institutional response to this failure, but scale limitations mean it can't yet solve it
|
|
||||||
|
|
||||||
**Extraction hints:**
|
|
||||||
- New claim: "The TEMPO pilot creates the first combined FDA enforcement-discretion + CMS reimbursement pathway for digital health hypertension management, but its scale (10 manufacturers, Medicare ACCESS participants only) targets a research population rather than the Medicaid and uninsured populations with the highest hypertension non-control rates"
|
|
||||||
- The TEMPO + OBBBA structural divergence is a strong claim candidate — it's an institutional contradiction occurring simultaneously
|
|
||||||
|
|
||||||
**Context:** TEMPO and the CMS ACCESS model are designed by CMMI (Center for Medicare & Medicaid Innovation) specifically to generate the real-world evidence that traditional FDA review requires. It's a workaround for the regulatory pathway problem where digital health companies need outcomes data to get clearance, but need clearance to collect outcomes data at scale.
|
|
||||||
|
|
||||||
## Curator Notes
|
|
||||||
|
|
||||||
PRIMARY CONNECTION: `the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification.md`
|
|
||||||
|
|
||||||
WHY ARCHIVED: Represents a structural escalation of FDA's January 2026 digital health deregulation — from general CDS guidance to a specific real-world evidence collection pathway targeting hypertension. The Medicare/Medicaid structural contradiction with OBBBA is a high-value claim candidate.
|
|
||||||
|
|
||||||
EXTRACTION HINT: Extract the TEMPO + OBBBA structural contradiction as a compound claim. Note the Medicare (TEMPO) vs. Medicaid (OBBBA) split — different populations, diverging infrastructure. The extractor should flag this for the broader "access infrastructure deteriorating while delivery infrastructure improves" pattern.
|
|
||||||
|
|
||||||
|
|
||||||
## Key Facts
|
|
||||||
- TEMPO pilot announced December 5, 2025 via Federal Register notice
|
|
||||||
- Statements of interest opened January 2, 2026
|
|
||||||
- Up to 10 manufacturers per clinical use area will be selected
|
|
||||||
- Four clinical use areas: early CKM, CKM, musculoskeletal, behavioral health
|
|
||||||
- Hypertension explicitly included in early CKM category
|
|
||||||
- ACP (Affordability Connectivity Program) subsidy discontinued June 2024
|
|
||||||
- National scale for hypertension: ~73 million affected US adults
|
|
||||||
- CMS ACCESS model includes rural patient adjustment
|
|
||||||
- Legal analysis sources: Wilson Sonsini, Manatt, ArentFox, McDermott
|
|
||||||
Loading…
Reference in a new issue